Zivo Bioscience holder buys 100,000 company shares
Zivo Bioscience, Inc. reported that an entity associated with 10% owner Mark E. Strome acquired additional common stock.
Rhea-AI Filing Summary
Zivo Bioscience, Inc. reported that an entity associated with 10% owner Mark E. Strome acquired additional common stock. On April 17, 2026, Strome Mezzanine Fund II, LP purchased 100,000 shares of Zivo common stock at $2.00 per share.
Following this transaction, the reporting group’s indirect holdings rose to 572,942 shares of common stock. The filing notes that the reporting persons may be deemed to share voting and investment power over these shares, while also disclaiming beneficial ownership for certain legal purposes.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Buyer: 100,000 shares
Net Buy
1 txn
Insider
STROME MARK E, STROME INVESTMENT MANAGEMENT LP, STROME GROUP, INC.
Role
10% Owner | Insider | Insider
Bought
100,000 shs ($200K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Common Stock | 100,000 | $2.00 | $200K |
Holdings After Transaction:
Common Stock — 572,942 shares (Indirect, By entity)
Footnotes (3)
- F1. The reported securities are owned directly by Strome Mezzanine Fund II, LP ("SMF II"), which were acquired pursuant to a Securities Purchase Agreement that SMF II entered into with the issuer.
- F2. Strome Investment Management, LP is the general partner of SMF II. Strome Group, Inc. is the general partner of Strome Investment Management, LP. Mark E. Strome is the President and CEO of Strome Group, Inc. Mr. Strome, Strome Investment Management, LP and Strome Group, Inc. (together, the "Reporting Persons") may be deemed to share voting and investment power for and to beneficially own the shares held by SMF II under Section 13(d) of the Securities Exchange Act of 1934 (the "Exchange Act").
- F3. Pursuant to Rule 16a-1(a)(4) of the Exchange Act, this filing shall not be deemed an admission that the Reporting Persons are, for purposes of Section 16 of the Exchange Act or otherwise, the beneficial owner of any equity securities reported herein.
Key Figures
Shares purchased: 100,000 shares
Purchase price: $2.00 per share
Shares held after: 572,942 shares
3 metrics
Shares purchased
100,000 shares
Common stock bought on April 17, 2026
Purchase price
$2.00 per share
Price paid for Zivo common stock
Shares held after
572,942 shares
Indirect common stock holdings following transaction
Key Terms
Securities Purchase Agreement, Section 13(d), Rule 16a-1(a)(4), Section 16, +1 more
5 terms
Securities Purchase Agreement financial
"owned directly by Strome Mezzanine Fund II, LP ("SMF II"), which were acquired pursuant to a Securities Purchase Agreement"
A securities purchase agreement is a written contract between a buyer and a seller outlining the terms for buying or selling financial assets such as stocks or bonds. It specifies details like the price, quantity, and conditions of the transaction, similar to a shopping list with agreed-upon terms. For investors, it provides clarity and legal protection when transferring ownership of these financial instruments.
Section 13(d) regulatory
"may be deemed to share voting and investment power for and to beneficially own the shares held by SMF II under Section 13(d) of the Securities Exchange Act"
A Section 13(d) filing is a public disclosure required under U.S. securities law when a person or group acquires more than 5% of a company’s registered equity and may influence control. The filer must report who owns the shares, how they were acquired, and any plans or intentions for the company, so the market and other shareholders can see if a large buyer is attempting a takeover or other strategic move. Think of it like a formal announcement that someone has crossed a threshold and is showing their hand.
Rule 16a-1(a)(4) regulatory
"Pursuant to Rule 16a-1(a)(4) of the Exchange Act, this filing shall not be deemed an admission"
Section 16 regulatory
"for purposes of Section 16 of the Exchange Act or otherwise, the beneficial owner of any equity securities"
Section 16 is a U.S. securities law rule that governs the trading and disclosure obligations of company insiders — typically officers, directors and large shareholders — to promote transparency and deter unfair profit-taking. It requires insiders to publicly report their stock trades and allows companies or the issuer to reclaim quick, short-term profits from certain insider trades, like a scoreboard and a refund policy that help investors see and limit possible insider advantage.
beneficial owner financial
"not be deemed an admission that the Reporting Persons are, for purposes of Section 16 of the Exchange Act or otherwise, the beneficial owner"
A beneficial owner is the person who ultimately owns or controls a financial asset or property, even if their name isn't directly on official documents. Think of it like someone who secretly holds the keys to a safe deposit box—others may appear to have access, but the true owner is the one who benefits from what's inside. Identifying beneficial owners helps ensure transparency and prevent illegal activities like money laundering or fraud.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Zivo Bioscience (ZIVO) report on this Form 4?
Zivo Bioscience reported that an entity associated with 10% owner Mark E. Strome bought 100,000 shares of common stock. The purchase occurred on April 17, 2026 at $2.00 per share, increasing the reporting group’s indirect holdings to 572,942 shares.
What is the reporting group’s total indirect ZIVO ownership after this transaction?
After the April 17, 2026 transaction, the reporting group’s indirect holdings total 572,942 shares of Zivo Bioscience common stock. This figure represents shares held through Strome Mezzanine Fund II, LP, with related entities potentially sharing voting and investment power as described in the filing’s footnotes.
AI-generated analysis. How Rhea-AI works. Not financial advice.
